A carregar...
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5190138/ https://ncbi.nlm.nih.gov/pubmed/27057638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8601 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|